Results 61 to 70 of about 117,776 (72)

Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial

BioDrugs, 2023
Huiping Li, Helong Zhang, Zhang Helong   +2 more
exaly  

UBE 2 QL 1 is Disrupted by a Constitutional Translocation Associated with Renal Tumor Predisposition and is a Novel Candidate Renal Tumor Suppressor Gene

Human Mutation, 2013
Noel Clarke, Anne-Bine Skytte, Eamonn Maher   +2 more
exaly  

A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of QL1206 to Denosumab Among Chinese Healthy Subjects

Frontiers in Pharmacology, 2020
Niu Junqi, Hong Zhang, Quan Liu
exaly  

Efficacy and Safety of Ranibizumab Biosimilar QL1205 in Neovascular Age-Related Macular Degeneration

Ophthalmology Retina
Miroslav Veith, Ignasi Jurgens, Agnieszka Nowosielska   +2 more
exaly  

Development of Reliable and Stable QL1-NMF Algorithm for Analyzing Environmental ELF Magnetic Signals

IEEE Journal of Selected Topics in Applied Earth Observations and Remote Sensing, 2018
Motoaki Mouri, Ichi Takumi, Hiroshi Yasukawa   +2 more
exaly  

Implementation of valid and stable algorithm of QL1-NMF for analyzing environmental elf magnetic signals

2017
Motoaki Mouri, Ichi Takumi, Hiroshi Yasukawa   +2 more
exaly  

Analysis and Prediction of QL14h by Database Application

Wireless Personal Communications, 2018
exaly  

QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial

British Journal of Cancer
Jin Zhang, Zhonghua Wang, Zhimin Shao
exaly  

AMPK activator 991 specifically activates SnRK1 and thereby affects seed germination in rice

Journal of Experimental Botany
Lin Chen, Chengqiang Ding, Yanfeng Ding   +2 more
exaly  

QL1701 (a proposed trastuzumab biosimilar) versus reference trastuzumab plus docetaxel as first-line therapy for HER2-positive metastatic breast cancer: a multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial

ESMO Open
exaly